

Elucidata and Sapien Biosciences to transform biobank assets into high quality AI products

05 June 2025 | News

Leading to precise patient outcomes at scale and lowering the cost of drug discovery



US-based Elucidata, a leader in data-centric AI for drug discovery and translational research, and Hyderabad-based Sapien Biosciences, India's first and largest commercial biobank with 300,000+ patient samples founded in partnership with Apollo Hospitals, have announced a strategic partnership to convert Sapien's extensive biobank assets into artificial intelligence (AI)-ready, multimodal data products for use in drug and diagnostic development.

Through this collaboration, Sapien will harness Elucidata's platform to integrate, standardise, and enrich its vast repository of biospecimens and curated clinical data, making them accessible for predictive modeling, synthetic data generation, and advanced genomics research.

The partnership reflects a shared focus on turning real-world patient data into high-value actionable insights that drive precision medicine and improve outcomes worldwide.

The first phase of the collaboration will focus on building AI models that infer genomic and transcriptomic insights from digital pathology images. By using NGS-annotated slides from Sapien's cancer biobank, the project will enable the generation of synthetic multi-modal datasets essential for next-generation diagnostic tools and tissue-sparing research strategies. This is particularly valuable for rare cancers and limited biopsy specimens.

In addition to oncology, the partnership will explore multi-disease use cases across Sapien's biobank, including cardiovascular, autoimmune, and neurological disorders, building synthetic clinicogenomic datasets that support pharma R&D and companion diagnostic development.